Alignment Healthcare (NASDAQ:ALHC) CEO Sells $4,136,240.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 298,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $13.88, for a total value of $4,136,240.00. Following the transaction, the chief executive officer directly owned 790,766 shares of the company’s stock, valued at approximately $10,975,832.08. The trade was a 27.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Trading Up 2.4%

ALHC opened at $13.52 on Thursday. The company’s 50 day moving average is $19.49 and its 200-day moving average is $19.26. Alignment Healthcare, Inc. has a 1-year low of $13.05 and a 1-year high of $25.12. The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 1.22. The company has a market cap of $2.80 billion, a P/E ratio of 71.16 and a beta of 1.10.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The firm’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.07 EPS. Equities research analysts predict that Alignment Healthcare, Inc. will post 0.17 earnings per share for the current fiscal year.

Institutional Trading of Alignment Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP grew its position in shares of Alignment Healthcare by 8.9% in the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock valued at $137,000 after buying an additional 566 shares during the last quarter. State of Alaska Department of Revenue raised its position in shares of Alignment Healthcare by 6.0% during the fourth quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after acquiring an additional 636 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of Alignment Healthcare by 6.3% in the third quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock worth $196,000 after acquiring an additional 665 shares during the period. Parallel Advisors LLC lifted its stake in shares of Alignment Healthcare by 87.7% in the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after acquiring an additional 773 shares during the period. Finally, Tidal Investments LLC lifted its stake in shares of Alignment Healthcare by 4.9% in the second quarter. Tidal Investments LLC now owns 18,094 shares of the company’s stock worth $253,000 after acquiring an additional 852 shares during the period. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALHC has been the topic of a number of research reports. Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. UBS Group reiterated a “neutral” rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. JPMorgan Chase & Co. cut their price target on Alignment Healthcare from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. TD Cowen restated a “buy” rating on shares of Alignment Healthcare in a report on Monday, August 3rd. Finally, Wolfe Research began coverage on Alignment Healthcare in a research note on Friday, April 17th. They issued an “outperform” rating and a $24.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Alignment Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: An analyst upgrade argued that Alignment’s valuation drawdown has created potential upside. The company’s second-quarter performance included 31% membership growth, a record-low medical benefits ratio, 48% adjusted EBITDA growth and increased full-year guidance. Alignment Healthcare: The Drawdown I Told You To Wait For Has Arrived
• Positive Sentiment: Recent quarterly results remain a fundamental support: Alignment reported earnings of $0.17 per share versus the $0.13 consensus estimate, while revenue rose 31.6% year over year to $1.34 billion. Analysts maintain a “Moderate Buy” consensus, with an average price target of $23.60.
• Neutral Sentiment: Institutional ownership is substantial at 86.19%, and several major investors recently increased or initiated positions. However, this support has not prevented the shares from trading near recent lows.
• Negative Sentiment: Multiple law firms, including Kaplan Fox, Frank R. Cruz and Pomerantz, announced investigations into possible securities-law violations and potential investor claims. The reports reference a 16% share-price decline on July 8 and allegations tied to possible financial manipulation. These are investigations and allegations, not established findings, but they add significant legal and reputational risk. Securities Fraud Investigation Into Alignment Healthcare Continues
• Negative Sentiment: Chief Executive Officer John Kao sold 298,000 shares worth approximately $4.1 million, reducing his direct ownership by 27.37%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which lessens—but does not eliminate—the negative signaling effect for investors. Alignment Healthcare Insider Trading

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.